Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis

被引:22
|
作者
Scamuffa, Nathalie [1 ,2 ]
Sfaxi, Fatma [1 ,2 ]
Ma, Jia [1 ,2 ]
Lalou, Claude [1 ,2 ]
Seidah, Nabil [3 ]
Calvo, Fabien [4 ]
Khatib, Abdel-Majid [1 ,2 ]
机构
[1] Univ Bordeaux 1, Angiogenesis Lab, F-33405 Talence, France
[2] INSERM, UMR 1029, F-33400 Talence, France
[3] Univ Montreal, Clin Res Inst Montreal IRCM, Lab Biochem Neuroendocrinol, Montreal, PQ, Canada
[4] Univ Paris 07, INSERM, UMRS 940, Inst Genet Mol, Paris, France
关键词
CELLS MALIGNANT PHENOTYPES; COLON-CARCINOMA CELLS; CANCER; GROWTH; INHIBITION; RECEPTOR; TUMORIGENICITY; INVASIVENESS; PROSEGMENTS; REPRESSES;
D O I
10.1093/carcin/bgt345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteolytic maturation of various precursor proteins by the proprotein convertase Furin is now considered as a crucial step in tumor progression and metastasis. Here, we report the repression of the malignant and metastatic potential of carcinoma cells by the prodomain region of Furin (ppFurin), a naturally occurring inhibitor of this convertase. Overexpression of ppFurin in carcinoma cells in a stable manner significantly reduced their convertase activity and ability to mediate processing of the Furin cancer-related substrates platelet-derived growth factor (PDGF)-A and insulin-like growth factor-I receptor precursors. Unprocessed platelet-derived growth factor-A produced by ppFurin expressing cells failed to induce the activation of Akt in the platelet-derived growth factor receptor-expressing cells NIH BALB/c-3T3 and treatment of ppFurin expressing cells with insulin-like growth factor-I failed to induce Akt phosphorylation, compared with controls. The malignant potential of ppFurin expressing cells was significantly reduced as revealed by the loss of anchorage-independent growth and survival that associated their increased chemosensitivity. In vivo, comparative studies revealed that expression of ppFurin in the carcinoma cells MDA-MB-231 and CT-26 cells inhibited tumor growth when subcutaneously inoculated in nude mice. The use of an experimental liver colorectal metastasis model revealed the reduced ability of metastatic carcinoma CT-26 cells to colonize the liver in response to intrasplenic/portal inoculation. Further analyses revealed reduced Furin activity in tumors derived from intrasplenic inoculated mice with ppFurin expressing CT-26 cells. This finding highlights the role of Furin in the malignant and metastatic potential of tumor cells and suggests the possible consideration of using its naturally occurring inhibitor ppFurin in anticancer therapy.
引用
收藏
页码:528 / 536
页数:9
相关论文
共 50 条
  • [1] Proprotein Convertase subtilisin Kexin 9 Inhibitors
    Pirillo, Angela
    Catapano, Alberico Luigi
    CARDIOLOGY CLINICS, 2018, 36 (02) : 241 - +
  • [2] Proprotein Convertase Subtilisin/Kexin Type 9
    Lu
    Daugherty
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (04) : E32 - E32
  • [3] The proprotein convertase furin in tumour progression
    Jaaks, Patricia
    Bernasconi, Michele
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (04) : 654 - 663
  • [4] Proprotein convertase subtilisin/kexin type 9 inhibition
    Marais, David A.
    Blom, Dirk J.
    Petrides, Francine
    Goueffic, Yann
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 511 - 517
  • [5] Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
    Sun, Xiaowei
    Essalmani, Rachid
    Day, Robert
    Khatib, Abdel M.
    Seidah, Nabil G.
    Prat, Annik
    NEOPLASIA, 2012, 14 (12): : 1122 - +
  • [6] Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
    Julius U.
    Tselmin S.
    Schatz U.
    Fischer S.
    Bornstein S.R.
    Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) : 45 - 50
  • [7] Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
    Spolitu, Stefano
    Dai, Wen
    Zadroga, John A.
    Ozcan, Lale
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 186 - 191
  • [8] Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
    Kotani, Kazuhiko
    Banach, Maciej
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : E78 - E82
  • [9] Depressive Symptoms and Proprotein Convertase Subtilisin/Kexin Type 9
    Macchi, C.
    Buoli, M.
    Favero, C.
    Pesatori, A.
    Vigna, L.
    Corsini, A.
    Sirtori, C.
    Bollati, V.
    Ruscica, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (05): : S92 - S92
  • [10] Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials
    Stoekenbroek, Robert M.
    Kastelein, John J. P.
    CURRENT OPINION IN CARDIOLOGY, 2018, 33 (03) : 269 - 275